Caligan Partners
$1.4B 13F equity value
28 Holdings
Latest filing 2026-03-31
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| LQDA | LIQUIDIA CORPORATION | 8,118,892 | $306M | 21.7% |
| ABVX | ABIVAX SA | 1,461,924 | $163M | 11.5% |
| RVMD | REVOLUTION MEDICINES INC | 1,652,808 | $161M | 11.4% |
| PCVX | VAXCYTE INC | 2,060,719 | $120M | 8.5% |
| XENE | XENON PHARMACEUTICALS INC | 1,393,027 | $81M | 5.7% |
| MLYS | MINERALYS THERAPEUTICS INC | 2,772,654 | $75M | 5.3% |
| EXEL | EXELIXIS INC | 1,553,262 | $67M | 4.7% |
| TNGX | TANGO THERAPEUTICS INC | 2,408,798 | $50M | 3.6% |
| TYRA | TYRA BIOSCIENCES INC | 1,276,968 | $49M | 3.5% |
| SYRE | SPYRE THERAPEUTICS INC | 878,127 | $44M | 3.1% |
Track Caligan Partners's 13F portfolio: $1.4B in reported holdings, 28 positions. Top holdings and quarterly changes on SentiSense.